Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Donald Jung"'
Autor:
Richard B. Lock, Malcolm A. Smith, Beverly A. Teicher, Tillman Pearce, Chi-Sheng Shia, Charles G. Mullighan, Kathryn G. Roberts, Komal S. Rathi, Donald Jung, Fanying Meng, Yuelong Guo, Stephen W. Erickson, Chelsea Mayoh, Narimanne El-Zein, Cara E. Toscan, Zhaohui Gu, Lisa McDermott, Connor D. Jones, Tara Pritchard, JianXin Duan, Kathryn Evans
Purpose:OBI-3424 is a highly selective prodrug that is converted by aldo-keto reductase family 1 member C3 (AKR1C3) to a potent DNA-alkylating agent. OBI-3424 has entered clinical testing for hepatocellular carcinoma and castrate-resistant prostate c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e1054e7a9f8ca25f82d9d09add67f38
https://doi.org/10.1158/1078-0432.c.6527832.v1
https://doi.org/10.1158/1078-0432.c.6527832.v1
Autor:
Fanying, Meng, Wan-Fen, Li, Donald, Jung, Chun-Chung, Wang, Tianyang, Qi, Chi-Sheng, Shia, Ren-Yu, Hsu, Yin-Cheng, Hsieh, Jianxin, Duan
Publikováno v:
Am J Cancer Res
AST-3424/OBI-3424 (denoted by 3424) is a novel prodrug bis-alkylating agent activated by AKR1C3. AKR1C3 is overexpressed in many types of cancer, particularly in liver, non-small cell lung, gastric, renal and CRPC cancer. Currently 3424 is being stud
Abstract 1220: Selective and broad anti-tumor activity of AKR1C3-activated prodrug AST-3424/OBI-3424
Autor:
Tianyang Qi, Donald Jung, Yin-Cheng Hsieh, Ren-Yu Hsu, Jian-Xin Duan, Wan-Fen Li, Chun-Chung Wang, Fanying Meng, Chi-Sheng Shia
Publikováno v:
Cancer Research. 81:1220-1220
AKR1C3 is overexpressed at both levels of protein and RNA in many types of cancer, particularly in liver, gastric, renal, CRPC and non-small cell lung cancer. High AKR1C3 expression is directly related to treatment resistance and poor prognosis. AST-
Autor:
Narimanne El-Zein, Fanying Meng, Komal S. Rathi, Stephen W. Erickson, Chelsea Mayoh, Yuelong Guo, Kathryn Evans, Connor D. Jones, Cara E. Toscan, Tillman Pearce, Charles G. Mullighan, Richard B. Lock, Jian-Xin Duan, Donald Jung, Kathryn G. Roberts, Zhaohui Gu, Malcolm A. Smith, Lisa McDermott, Chi-Sheng Shia, Beverly A. Teicher, Tara Pritchard
Publikováno v:
Clin Cancer Res
Purpose: OBI-3424 is a highly selective prodrug that is converted by aldo-keto reductase family 1 member C3 (AKR1C3) to a potent DNA-alkylating agent. OBI-3424 has entered clinical testing for hepatocellular carcinoma and castrate-resistant prostate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12232e5a1100ba377a116eb067dda2f7
https://europepmc.org/articles/PMC6635081/
https://europepmc.org/articles/PMC6635081/
Autor:
Peter N. Lohstroh, Donald Jung, Luis Lopez-Lazaro, Stephen R. Dueker, Lawrence Fleckenstein, Xin-Ping Fang, Mark Baker, Jangsik Shin, Carrie A. Morris, Li-Quan Wang, Rolf Pokorny, Stephan Duparc, Isabelle Borghini-Fuhrer
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 40:75-86
This was a single dose mass balance and metabolite characterization study of the antimalarial agent pyronaridine. Six healthy male adults were administered a single oral dose of 720 mg pyronaridine tetraphosphate with 800 nCi of radiolabeled (14)C-py
Autor:
Carrie A. Morris, Beesan Tan, Isabelle Borghini-Fuhrer, Lawrence Fleckenstein, Stephan Duparc, Chang-Sik Shin, Donald Jung
Publikováno v:
Antimicrobial Agents and Chemotherapy. 57:5889-5900
Despite the important role of the antimalarial artesunate and its active metabolite dihydroartemisinin (DHA) in malaria treatment efforts, there are limited data on the pharmacokinetics of these agents in pediatric patients. This study evaluated the
Autor:
A. Ricart, E. Gabriella Chiorean, James J. Schlesselman, Khaled A. Tolba, Joseph D. Rosenblatt, Luis E. Raez, Kyriakos P. Papadopoulos, Metin Kurtoglu, Robert S. DiPaola, Donald Jung, Stewart Kroll, Mark N. Stein, V. K. Langmuir, Caio Max S. Rocha Lima, Theodore J. Lampidis
Publikováno v:
Cancer Chemotherapy and Pharmacology. 71:523-530
This phase I trial was initiated to evaluate the safety, pharmacokinetics (PK) and maximum tolerated dose (MTD) of the glycolytic inhibitor, 2-deoxy-D-glucose (2DG) in combination with docetaxel, in patients with advanced solid tumors.A modified acce
Publikováno v:
Xenobiotica. 42:687-700
The metabolism and excretion of a hypoxically activating prodrug for the treatment of cancer, TH-302, were studied in beagle dogs following intravenous administration of 20 mg/kg (14)C-TH-302. TH-302 was extensively metabolized with total recovery of
Autor:
Janthima Methaneethorn, Luis Lopez-Lazaro, Lawrence Fleckenstein, Isabelle Borghini-Fuhrer, Carrie A. Morris, Stephan Duparc, Chang-Sik Shin, Rolf Pokorny, Donald Jung
Publikováno v:
The American Journal of Tropical Medicine and Hygiene
A multiple dose, parallel group study was conducted to assess for a drug-drug interaction between the pyronaridine/artesunate (PA) combination antimalarial and ritonavir. Thirty-four healthy adults were randomized (1:1) to receive PA for 3 days or PA
Publikováno v:
Xenobiotica. 42:372-388
The metabolism, pharmacokinetics and excretion of a hypoxically activating prodrug developed for the treatment of cancer, TH-302, were studied in rats following intravenous administration of 50 mg/kg [(14)C]-TH-302. The pharmacokinetics of TH-302 was